Recursion
@RecursionPharma
Decoding biology to radically improve lives. The industrial revolution of drug discovery is here.
You might like
🧠 How the Microglia Map will help guide new insights and therapeutic pathways for treating neurodegenerative diseases. In a new story in @Tech_Networks, incoming CEO and President Najat Khan, PhD shared insights into the creation of the Microglia Map in partnership with @Roche…
Fantastic turnout for the BoltzGen seminar in London at Recursion's office last night! Huge thanks to everyone who joined, the energy in the room was great, and it’s inspiring to see many already testing new BoltzGen designs on real problems.
🎉 Incoming CEO Najat Khan was named one of 2025’s Fiercest Women in Life Sciences from @FiercePharma. Each year, the list celebrates women who are making a powerful impact across biopharma and medtech, and have strong track records in innovation, leadership, and mentorship.…
Leveraging the power of patient data. On Wed., Nov. 19, 8am PT / 11am ET, join us for a live webinar with @TempusAI to discuss "A new era of biopharma R&D: The TechBio revolution – Realities and the next frontier." Panelists @donnella_hayley, VP of Frontier Research at…
We're headed to @Jefferies Global Healthcare Conference & London Life Sciences Week! 🧬 Just added - we’re now partnering on a BoltzGen Presentation on Nov. 19, 5-9pm at Recursion’s London office in King's Cross. Get the latest details on the new BoltzGen model and discuss the…
🔹 Presenting REC-102: Preclinical in vivo updates for a potential ENPP1 inhibitor for the treatment of hypophosphatasia (HPP). On Sept. 6, Recursion collaborators in the lab of José Luis Millán, PhD, Professor of the Human Genetics Program at Sanford Children’s Health Research…
Breaking barriers to make better medicines. At the inaugural @TEDx Tribeca on Dec. 3, Recursion incoming CEO and current Chief R&D Officer and Chief Commercial Officer Najat Khan, PhD will present her personal journey merging science and technology to make new medicines and…
Yesterday, Recursion announced its third quarter 2025 financial results and business updates, with continued progress across our pipeline, partnerships, and the Recursion OS AI-driven platform. 🚀 Highlights included: ▪️ A $30 million milestone from @Roche and @genentech for the…
Join us today at 8am ET / 6am MT / 1pm BST for our Q3 2025 (L)earnings Call. Questions may be submitted at forms.gle/TQ4vgUTLKsFmik…
Today, Recursion announced its third quarter 2025 financial results and business updates, along with a leadership transition plan to drive the next phase of its growth. Effective January 1st, @RecursionChris, Co-Founder and CEO, will transition to Chairman of the Board, Najat…
Recursion announced today that it will participate in the following upcoming investor conferences: ▪️ Nov. 11, 8 am ET: @GuggenheimPtnrs 2nd Annual Healthcare Innovation Conference in Boston ▪️ Nov. 18, 10:30 am GMT: @Jefferies Global Healthcare Conference in London 👉 Tune in…
👩🔬 A new round of Returnship opportunities are now available! Recursion’s 16-week Returnship Program gives those who have taken a hiatus (2+ years) from the STEM industry the opportunity to return to the workforce, providing hands-on experience on cutting edge tools and…
In case you missed it – our (L)earnings Call will be held on Wednesday, November 5. Learn more about our just-announced Microglia Map with Roche and Genentech along with other business updates and third quarter 2025 financial results on Wednesday, November 5, 2025 at 8:00 am ET…
📈Tracking investment trends in TechBio. The third episode of our TechBio Talks podcast is now live, featuring @RecursionChris in conversation with leading AI investor @nathanbenaich of @airstreet. Learn about the evolving landscape of AI in drug discovery, the biggest trends…
Ever wonder what the next 5 years of AI in biology & venture will look like? @NathanBenaich (@airstreet) and I unpack it on #TechBioTalks — from AI-first investing to the true moats in TechBio. Catch the full convo → (link in comments)
If you’re working in AI, you most likely saw the just-released 2025 State of AI Report from @nathanbenaich, Founder and General Partner at @airstreet. The annual report is a must-read deep dive into the state of the industry, with this year’s highlights including: reasoning going…
We're headed to the Broad. On Nov. 7, 3:30pm @orenkraus, Associate Director of Machine Learning at Recursion, will present on “Foundation Models for Early Drug Discovery” at the @broadinstitute 's Machine Learning in Drug Discovery Symposium. The hybrid event will highlight…
United States Trends
- 1. Cowboys 28.1K posts
- 2. Colts 36.8K posts
- 3. Chiefs 74.4K posts
- 4. Giants 81.8K posts
- 5. Gibbs 16.1K posts
- 6. Jameis 40.4K posts
- 7. Jerry Jeudy 2,511 posts
- 8. Turpin 2,351 posts
- 9. Lions 59.3K posts
- 10. #FlyEaglesFly 8,653 posts
- 11. Steelers 51.5K posts
- 12. Bears 68.2K posts
- 13. JJ McCarthy 7,637 posts
- 14. Shedeur 38.4K posts
- 15. Smitty 3,295 posts
- 16. Mahomes 18.6K posts
- 17. Vikings 30.5K posts
- 18. Shane Bowen 2,686 posts
- 19. Ceedee 3,185 posts
- 20. Tomlin 7,558 posts
You might like
-
Insilico Medicine
@InSilicoMeds -
Generate:Biomedicines
@generate_biomed -
george church
@geochurch -
Bits in Bio
@bitsinbio -
Enveda
@lifeschemistry -
Machine learning for protein engineering seminar
@ml4proteins -
Chris Gibson
@RecursionChris -
Isomorphic Labs
@IsomorphicLabs -
SynBioBeta
@SynBioBeta -
Valence Labs
@valence_ai -
Manifold Bio
@ManifoldBio -
Endpoints News
@endpts -
Dyno Therapeutics, Inc.
@Dyno_Tx -
Anne Carpenter, PhD
@DrAnneCarpenter -
Mohammed AlQuraishi
@MoAlQuraishi
Something went wrong.
Something went wrong.